These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 1880439)
1. Transdermal scopolamine use in the control of narcotic-induced nausea. Ferris FD; Kerr IG; Sone M; Marcuzzi M J Pain Symptom Manage; 1991 Aug; 6(6):389-93. PubMed ID: 1880439 [TBL] [Abstract][Full Text] [Related]
2. Withdrawal symptoms after discontinuation of transdermal scopolamine therapy: treatment with meclizine. Patel PN; Ezzo DC Am J Health Syst Pharm; 2009 Nov; 66(22):2024-6. PubMed ID: 19890085 [TBL] [Abstract][Full Text] [Related]
3. Transderm scopolamine for the control of perioperative nausea. Stromberg BV; Reines DH; Ackerly J Am Surg; 1991 Nov; 57(11):712-5. PubMed ID: 1746779 [TBL] [Abstract][Full Text] [Related]
4. Prochlorperazine and transdermal scopolamine added to a metoclopramide antiemetic regimen. A controlled comparison. Malone JM; Christensen CW; Yashinsky D; Malviya VK; Deppe G J Reprod Med; 1990 Oct; 35(10):932-4. PubMed ID: 2246759 [TBL] [Abstract][Full Text] [Related]
5. Transdermal scopolamine-induced neurologic deficits in patients with cancer. Friedberg MH; Glantz MJ R I Med; 1994 May; 77(5):141-2. PubMed ID: 8019013 [No Abstract] [Full Text] [Related]
9. Premedication with promethazine and transdermal scopolamine reduces the incidence of nausea and vomiting after intrathecal morphine. Tarkkila P; Törn K; Tuominen M; Lindgren L Acta Anaesthesiol Scand; 1995 Oct; 39(7):983-6. PubMed ID: 8848904 [TBL] [Abstract][Full Text] [Related]
10. Transdermal scopolamine reduces nausea and vomiting after outpatient laparoscopy. Bailey PL; Streisand JB; Pace NL; Bubbers SJ; East KA; Mulder S; Stanley TH Anesthesiology; 1990 Jun; 72(6):977-80. PubMed ID: 2140929 [TBL] [Abstract][Full Text] [Related]
11. Nausea prophylaxis using transdermal scopolamine in the setting of patient-controlled analgesia. Harris SN; Sevarino FB; Sinatra RS; Preble L; O'Connor TZ; Silverman DG Obstet Gynecol; 1991 Oct; 78(4):673-7. PubMed ID: 1923171 [TBL] [Abstract][Full Text] [Related]
12. Transdermally administered scopolamine vs. dimenhydrinate. I. Effect on nausea and vertigo in experimentally induced motion sickness. Pyykkö I; Schalén L; Jäntti V Acta Otolaryngol; 1985; 99(5-6):588-96. PubMed ID: 4024909 [TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of transdermal scopolamine for the prevention of postoperative nausea and vomiting: a quantitative systematic review. Kranke P; Morin AM; Roewer N; Wulf H; Eberhart LH Anesth Analg; 2002 Jul; 95(1):133-43, table of contents. PubMed ID: 12088957 [TBL] [Abstract][Full Text] [Related]
14. Double blind comparison of transdermal hyoscine and placebo for the prevention of postoperative nausea. Koski EM; Mattila MA; Knapik D; Toivanen T; Ruusukallio H; Andersson P; Freudenthal Y Br J Anaesth; 1990 Jan; 64(1):16-20. PubMed ID: 2405893 [TBL] [Abstract][Full Text] [Related]
15. Central anticholinergic syndrome in a pediatric patient following transdermal scopolamine patch placement. Holland MS Nurse Anesth; 1992 Sep; 3(3):121-4. PubMed ID: 1445954 [TBL] [Abstract][Full Text] [Related]
16. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects. Shupak A; Gordon CR; Spitzer O; Mendelowitz N; Melamed Y Pharmatherapeutica; 1989; 5(6):365-70. PubMed ID: 2594820 [TBL] [Abstract][Full Text] [Related]